Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
1,663
Period ended Dec 31, 2025
Change on a year earlier
+46.0%
1,139 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,663 | +46.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,139 | +43.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 793 | +30.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 608 | +9.2% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 557 | +21.4% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 459 | +22.1% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 376 | +5.0% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 358 | – | Form 10-K (filed 2021-02-09) ↗ |
Cite this data
StockData. (2026). Amgen Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_repatha_us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.